NASDAQ:HSCS HeartSciences (HSCS) Stock Price, News & Analysis $1.67 -0.13 (-6.96%) Closing price 05/29/2026 03:59 PM EasternExtended Trading$1.70 +0.04 (+2.10%) As of 05/29/2026 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About HeartSciences Stock (NASDAQ:HSCS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get HeartSciences alerts:Sign Up Key Stats Today's Range$1.63▼$1.8350-Day Range$1.67▼$2.5752-Week Range$1.63▼$6.47Volume54,809 shsAverage Volume21,817 shsMarket Capitalization$5.31 millionP/E RatioN/ADividend YieldN/APrice Target$8.00Consensus RatingHold Company Overview HeartSciences, Inc. (NASDAQ: HSCS) is a medical device company focused on the development and commercialization of advanced, non‐invasive cardiac diagnostic technologies. The company’s flagship product, MyoVista, is a high‐fidelity electrocardiograph (ECG) designed to detect subtle changes in cardiac function that may indicate myocardial ischemia or left ventricular dysfunction. By leveraging high‐frequency wavelet analysis within the QRS complex, MyoVista provides clinicians with enhanced visualization and analytical capabilities that extend beyond those of standard ECG systems. HeartSciences supports the MyoVista system with an integrated software suite that automates data analysis and report generation, facilitating seamless integration into existing clinical workflows. The technology has received regulatory clearance in key markets including the United States and European Union, and the company continues to forge distribution partnerships and develop direct sales channels to broaden its reach among cardiology practices, hospitals and primary care providers. Concurrently, HeartSciences is advancing its research efforts to explore additional clinical applications and refine its diagnostic algorithms. Headquartered in Bothell, Washington, HeartSciences maintains research and development operations in the United States and collaborates with academic and clinical institutions to validate and expand its platform. As a publicly traded company on the NASDAQ exchange, HeartSciences is led by an executive team and governed by a board of directors committed to driving innovation in non‐invasive cardiovascular diagnostics. Through ongoing product development and strategic partnerships, the company aims to enhance patient outcomes and support clinicians with robust, data‐driven diagnostic tools.AI Generated. May Contain Errors. Read More HeartSciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks59th Percentile Overall ScoreHSCS MarketRank™: HeartSciences scored higher than 59% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingHeartSciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialHeartSciences has a consensus price target of $8.00, representing about 379.0% upside from its current price of $1.67.Amount of Analyst CoverageHeartSciences has only been the subject of 2 research reports in the past 90 days.Read more about HeartSciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for HeartSciences are expected to grow in the coming year, from ($3.28) to ($3.10) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of HeartSciences is -0.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of HeartSciences is -0.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHeartSciences has a P/B Ratio of 9.28. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about HeartSciences' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.24% of the float of HeartSciences has been sold short.Short Interest Ratio / Days to CoverHeartSciences has a short interest ratio ("days to cover") of 1.45, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in HeartSciences has recently increased by 19.04%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHeartSciences does not currently pay a dividend.Dividend GrowthHeartSciences does not have a long track record of dividend growth. News and Social Media4.3 / 5News SentimentN/A News SentimentHeartSciences has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.83 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for HeartSciences this week, compared to 1 article on an average week.Search Interest1 people have searched for HSCS on MarketBeat in the last 30 days. MarketBeat Follows1 people have added HeartSciences to their MarketBeat watchlist in the last 30 days. Company Ownership0.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, HeartSciences insiders have not sold or bought any company stock.Percentage Held by Insiders4.90% of the stock of HeartSciences is held by insiders.Percentage Held by Institutions17.24% of the stock of HeartSciences is held by institutions.Read more about HeartSciences' insider trading history. Receive HSCS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for HeartSciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HSCS Stock News HeadlinesHeartSciences Signs Commercial Agreement with North Shore Health, the First Hospital Deployment from the Cibolo Health NetworkMay 19, 2026 | globenewswire.comHeartSciences Stockholders Approve Director Election and Equity PlanMay 6, 2026 | tipranks.comOne hidden supplier shipped 5 billion parts to SpaceXMost investors are focused on the historic $1.75 trillion SpaceX IPO expected around June 30. But there's a lesser-known angle that could matter more to your portfolio. One under-the-radar tech firm has already shipped 5 billion critical components to SpaceX - making it a linchpin of the operation. Because SpaceX has been private, this partnership has gone almost entirely unnoticed by Wall Street.May 30 at 1:00 AM | Weiss Ratings (Ad)HeartSciences Inc.: HeartSciences Signs First SaaS Revenues Agreement following full launch of MyoVista InsightsMay 5, 2026 | finanznachrichten.deHeartSciences Signs First SaaS Revenues Agreement following full launch of MyoVista Insights™May 5, 2026 | globenewswire.comHeartSciences Reminds Its Shareholders to Submit Their Vote at the Upcoming April 30, 2026, Annual Shareholders MeetingApril 14, 2026 | globenewswire.comHeartSciences COO and Longtime Board Member Passes AwayApril 3, 2026 | tipranks.comHeartSciences Inc.March 31, 2026 | cnn.comSee More Headlines HSCS Stock Analysis - Frequently Asked Questions How have HSCS shares performed this year? HeartSciences' stock was trading at $3.09 at the start of the year. Since then, HSCS stock has decreased by 46.0% and is now trading at $1.67. How were HeartSciences' earnings last quarter? HeartSciences Inc. (NASDAQ:HSCS) announced its quarterly earnings results on Monday, March, 16th. The company reported ($0.63) earnings per share for the quarter, topping analysts' consensus estimates of ($0.84) by $0.21. When did HeartSciences' stock split? HeartSciences shares reverse split on the morning of Friday, May 17th 2024.The 1-100 reverse split was announced on Friday, May 17th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 17th 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. When did HeartSciences IPO? HeartSciences (HSCS) raised $9 million in an initial public offering (IPO) on Wednesday, June 15th 2022. The company issued 1,800,000 shares at $4.50-$5.50 per share. The Benchmark Company served as the underwriter for the IPO. How do I buy shares of HeartSciences? Shares of HSCS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of HeartSciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that HeartSciences investors own include Meta Platforms (META), Cardio Diagnostics (CDIO), Invesco QQQ (QQQ), RH (RH), ExxonMobil (XOM), Amarin (AMRN) and American Express (AXP). Company Calendar Last Earnings3/16/2026Today5/30/2026Next Earnings (Estimated)7/23/2026Fiscal Year End4/30/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (3m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 HSCS's financial health is in the Yellow zone, according to TradeSmith. HSCS has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MEDICAL INFO SYS Sub-IndustryMedical Equipment Current SymbolNASDAQ:HSCS CIK1468492 Webheartsciences.com Phone682-237-7781FaxN/AEmployees10Year FoundedN/APrice Target and Rating Average Price Target for HeartSciences$8.00 High Price Target$8.00 Low Price Target$8.00 Potential Upside/Downside+379.0%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($4.94) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$8.77 million Net MarginsN/A Pretax Margin-106,062.50% Return on Equity-333.50% Return on Assets-140.18% Debt Debt-to-Equity Ratio0.16 Current Ratio1.19 Quick Ratio1.04 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.18 per share Price / Book9.28Miscellaneous Outstanding Shares3,180,000Free Float3,029,000Market Cap$5.31 million OptionableNot Optionable Beta2.03 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:HSCS) was last updated on 5/30/2026 by MarketBeat.com Staff. From Our PartnersLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredPresident Trump just sparked a stock market MELT UPThe real reason Musk, Huang, Cook, and Fink just flew to Beijing Last week, the CEOs of Nvidia, Apple, Spac...Stansberry Research | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredSkip the Line Opportunity: The SpaceX IPOFormer tech executive and angel investor Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before their h...Brownstone Research | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding HeartSciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share HeartSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
